Skip to main content

Grafa News and Videos — Page 1527

Latest

Grafa
Industrials

Braiin announces 3-for-1 stock split to enhance retail investor accessibility

Braiin (NASDAQ:BRAI), a global provider of integrated industrial technology and AI-driven agricultural solutions, announced on April 10, 2026, that its Board of Directors and shareholders have approved a three-for-one forward stock split.

Read more: Braiin announces 3-for-1 stock split to enhance retail investor accessibility
Grafa
Defence

Lockheed Martin secures $4.7B contract to triple PAC-3 missile production

Lockheed Martin (NYSE:LMT) announced on April 10, 2026, that it has received a $4.7 billion undefinitized contract action (UCA) from the U.S. government to rapidly accelerate the production of PAC-3 Missile Segment Enhancement (MSE) interceptors.

Read more: Lockheed Martin secures $4.7B contract to triple PAC-3 missile production
Grafa
Technology

CoreWeave secures Anthropic as key infrastructure partner to scale Claude AI models

CoreWeave (NASDAQ:CRWV), the specialized cloud provider for large-scale artificial intelligence, announced a multi-year agreement today with Anthropic to support the development and deployment of the Claude family of AI models.

Read more: CoreWeave secures Anthropic as key infrastructure partner to scale Claude AI models
Grafa

Verastem Oncology reports sustained two-year efficacy for LGSOC combination rherapy at SGO 2026

Verastem Oncology (NASDAQ:VSTM) presented updated two-year median follow-up data today from its pivotal Phase 2 RAMP 201 trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting.

Read more: Verastem Oncology reports sustained two-year efficacy for LGSOC combination rherapy at SGO 2026
Grafa

Whitehawk Therapeutics data at SGO 2026 positions MUC16 as superior ADC target

Whitehawk Therapeutics (NASDAQ:WHWK), a clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs), presented compelling real-world evidence at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.

Read more: Whitehawk Therapeutics data at SGO 2026 positions MUC16 as superior ADC target

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift